ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)

NCT06378138 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

226

Enrollment

INDUSTRY

Sponsor class

Conditions

Hematologic Malignancies

Interventions

DRUG: ICP-248
DRUG: Orelabrutinib

Sponsor

Beijing InnoCare Pharma Tech Co., Ltd.